Varespladib is an inhibitor of the IIa, V, and X isoforms of secretory phospholipase A2. The molecule acts as an anti-inflammatory agent by disrupting the first step of the arachidonic acid pathway of inflammation. It is a small molecule reversible inhibitor available as both an active moiety and as an oral methyl prodrug (varespladib methyl, LY333013) with formulations investigated for oral and parenteral use. Mechanistically, varespladib binds the catalytic site of sPLA2 isoforms, preventing hydrolysis of membrane phospholipids and reducing formation of free arachidonic acid and lysophospholipids, which in turn attenuates downstream eicosanoid and platelet activating factor signaling. Preclinical and clinical pharmacology work demonstrates isoform-selective potency and dose-dependent suppression of circulating sPLA2 activity and biomarkers of inflammation. Physicochemical properties relevant for formulation include moderate aqueous solubility for the salt forms, susceptibility to hydrolytic and oxidative degradation under stressed conditions, and the need for controlled manufacturing and storage to maintain assay and purity.
Parent: Varespladib
Typical impurity and related compound profile for varespladib active pharmaceutical ingredient and its prodrug includes synthetic intermediates, residual solvents, hydrolysis products, oxidative degradation products, and trace metal residues. A representative quality specification for commercial or clinical supply commonly follows ICH guidance and may include limits such as: any individual unspecified impurity not greater than 0.10 percent area by validated HPLC, any specified related compound not greater than 0.50 percent, total impurities not greater than 1.5 to 2.0 percent, residual solvents within ICH Q3C permitted daily exposure limits and class-specific ppm limits, and heavy metals below typical pharmacopeial thresholds (for example less than 10 to 20 ppm depending on method and route). Specific impurity identification, qualification thresholds, and analytical limits are established per the dossier and regulatory submission for each formulation lot.
Varespladib was originally discovered and developed under the designation LY315920 by Lilly Research Laboratories; subsequent development, clinical evaluation, and manufacturing have involved different sponsors and contract manufacturers for specific programs and formulations. Commercial and clinical supply arrangements vary by program and region.
Pharmacokinetic profiles depend on formulation, route, and prodrug versus parent compound. Oral varespladib methyl is designed for rapid absorption with conversion to the active varespladib species; Tmax is typically within a few hours after dosing. Systemic exposure shows dose proportionality across studied ranges, with a plasma elimination half life that supports once or twice daily dosing in reported clinical studies. The compound shows significant plasma protein binding, metabolic transformation including hydrolytic conversion of the methyl prodrug to the active acid, and elimination of metabolites via renal and fecal routes. Exact PK parameters such as clearance, volume of distribution, and half life must be taken from the specific formulation clinical study report or label for definitive values.
